We are a biotech and healthcare Investors
Investing across venture capital, growth and private equity.
We partner with scientists, founders and operators to build and scale high-impact companies that advance human health and wellbeing.
We combine scientific understanding with commercial and operational expertise - enabling us to identify opportunities, encourage innovation and create long-term value creation.
Our multi stage investment approach ensures we can support businesses from proof of concept to market leading positions.
Our Investment Focus
Venture Capital
Backing pioneering biotech, deep tech and healthcare spinouts from leading universities, and helping bridge the gap between research and commercialisation.
- University spinouts in biotech, deeptech and Techbio
- IP heavy innovations with defensibility
- Platforms solving global health challenges.
Growth Capital
Fuelling the expansion of proven healthcare businesses ready to scale.
- Therapeutic growth equity for late-stage biotechs
- Medical devices expanding manufacturing and distribution
- Healthcare service platforms scaling across Europe.
Private Equity
Partnering with or acquiring established healthcare businesses to drive operational excellence and international expansion.
- Biopharma services (CDMOs, CROs, pharma outsourcing
- Medical devices and diagnostics across the value chain.
- Therapeutics with untapped growth opportunities.
Venture Capital
Backing pioneering biotech, deep tech and healthcare spinouts from leading universities, and helping bridge the gap between research and commercialisation.
- University spinouts in biotech, deeptech and Techbio
- IP heavy innovations with defensibility
- Platforms solving global health challenges.
Growth Capital
Fuelling the expansion of proven healthcare businesses ready to scale.
- Therapeutic growth equity for late-stage biotechs
- Medical devices expanding manufacturing and distribution
- Healthcare service platforms scaling across Europe.
Private Equity
Partnering with or acquiring established healthcare businesses to drive operational excellence and international expansion.
- Biopharma services (CDMOs, CROs, pharma outsourcing
- Medical devices and diagnostics across the value chain.
- Therapeutics with untapped growth opportunities.
The Biotech Opportunity Landscape
60%
of the world’s physical inputs could, in principle, be made using biological means.
45%
of the global disease burden could be addressed using science that is conceivable today.
$1.42
trillion was the global pharmaceutical revenues by the end of 2021, up from $390 billion just 20 years earlier.
43
of the top research universities for biotech in the world are based in the UK and Europe.
$280
billion combined revenue patent cliff by 2030 across 50 products – not patents.
350
million people across the globe suffer from a rare genetic disease.
537
million people have diabetes with the number expected to rise to 783 million by 2045.
1317
active university spin-out businesses operate in the UK, with 14 exits from UK spin-outs in 2023.
43
of the top research universities for biotech in the world are based in the UK and Europe.
$280
billion combined revenue patent cliff by 2030 across 50 products – not patents.
350
million people across the globe suffer from a rare genetic disease.
537
million people have diabetes with the number expected to rise to 783 million by 2045.
1317
active university spin-out businesses operate in the UK, with 14 exits from UK spin-outs in 2023.